Philip Morris International (PMI) has made an offer to acquire Vectura Group for approximately $1.45 billion, a move that’s making headlines in the pharmaceutical world. Previously, Vectura Group had accepted an acquisition bid from The Carlyle Group back in May 2021.
Based in the United Kingdom, Vectura Group’s focus is on inhaled drug delivery solutions that aid its partners to provide their therapies to patients. As of now, Vectura Group’s portfolio consists of 13 inhaled and 11 non-inhaled products sold by the company’s pharmaceutical partners. The company also has several drugs that are in the clinical development stage. For PMI, this acquision would allow it to further develop prescription drug and over-the-counter products as the deal would give PMI access to over 200 researchers that specialize in formulation, inhalation, and clinical manufacturing. As PMI shifts its focus away from combustible tobacco products, the acquisition of Vectura Group would help it accelerate the development of inhaled and oral products. This would also complement its last acquisition of Fertin Pharma, announced weeks ago [read more here].